SC
ALNY icon

Stephens Consulting’s Alnylam Pharmaceuticals ALNY Stock Holding History

Stephens Consulting’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5
Closed -$1.63K – 423
2025
Q2 		$1.63K Buy
+5
New +$1.38K ﹤0.01% 541

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Stephens Consulting's ALNY Position: Q3 2025 in Review

Stephens Consulting sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 5 shares — an estimated $1.63K sold.

Stephens Consulting first reported a position in ALNY in Q2 2025 and held it in 1 quarter. The position peaked at $1.63K in Q2 2025. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Stephens Consulting reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Stephens Consulting sold 5 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $1.63K.
  • Stephens Consulting first reported a position in Alnylam Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Stephens Consulting's Alnylam Pharmaceuticals position peaked at $1.63K in Q2 2025.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.